HIV/AIDS EDITION: THE CORPORATE REPUTATION OF PHARMA IN 2021
The Patient Perspective? HIV/AIDS edition The views of 168 cancer patient groups
PatientView is today publishing the results of its latest ?Corporate Reputation of Pharma? survey?HIV/AIDS edition, now in its 9th year, and two years into the Covid-19 pandemic. Running between November 2021 to February 2022, the survey collected the opinions of 168 HIV/AIDS patient groups on the performance of the pharmaceutical industry during 2021. Patient groups possess a unique understanding of the needs of the patients, and represent the collated views of patients. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. At the same time, many patient groups are also familiar with the complexities of pharma?s business?85% of the HIV/AIDS patient groups responding to the 2021 ?Corporate Reputation of Pharma? survey worked or partnered with at least one pharma company that year. Continue reading for details on: · How PatientView measures pharma?s corporate reputation from a patient perspective; · The headline results of the 2021 survey, from the perspective of HIV/AIDS patient groups; · &nbs...
